??????????????????

????

□□□

???????

□□□

□□□□□□□ /□□□□□□□

□□□

????????

□□□

□□□

□□□□□ Double-blind Trial□	□□□□□

□□□□□□	Standard Operation Procedure, SOP
□□□□	Single-blind Trial
□□□	Single-dummy
□□□□□□	Electronic Data Capture, EDC
□□□□	Independent Review
□□□□□□□	Independent Review Committee, IRC
□□□□□□□	Unblinded Interim Analysis
□□□□	Allocation Concealment
□□□□□□	Patient Reported Outcome, PRO
□□□□	Encryption Technology
□□□□□□□	Interactive Response System, IRS
□□	Unblinding
□□□□	Emergent Unblinding
□□□□	Open-label Trial
□□□	Auditor
□□□	Clinical Research Associate, CRA
□□□□□	Clinical Research Coordinator, CRC
□□	Allocation Schedule
□□	Blinding/Masking
□□□□	Blinding Monitoring
□□□□	Maintenance of Blind
□□□□□□	Blinded Data Review
□□□□□□	Unblinding for Interim Analysis
□□□□□	Blockchain Technology
□□□□□□□	Data Monitoring Committee, DMC
□□□□	Double-blind Trial
□□□	Double-dummy
□□□□□	Internet of Things Technology
□□□□□□	Modern Logistics Technology
□□□□□□	Serious Adverse Event, SAE
□□□□	Drug Coding
□□□□	Unintentional/Accidental Unblinding

□□□□	Unblinding at the End
□□□□□□□	Central Randomization System
□□□□□	Principal Investigator, PI
□□□□□	Traceability Code Technology

????

[1] ICH. E9: Statistical Principles for Clinical Trials. 1998.

[2] □□□□□□□□□□□□ . □□□□□□□□□□□□□□□□□ . 2016.

[3] □□□□□□□□□ . □□□□□□□□□□□□□□□□□□□□□□□□□□□□ . 2018.

[4] □□□□□□□□□ . □□□□□□□□□□□□□□□□□□□□□□□□ . 2020.

[5] □□□□□□□□□ . □□□□□□□□□□□□□ . 2020.

[6] □□□□□□□□□ .□□□□□□□□□□□□□□□□□□□□□□ . 2021.

[7] □□□□□□□□□ . □□□□□□□□□□□ . 2021.

[8] □□□□□□□□□ .□□□□□□□□□□□□□ 2010 □□□□□□□□□□□□□□□□□□□□□ . 2022.

[9] □□□□□□□□□ . □□□□□□□□□□□□□□□□□□□□□□□□ . 2022.

[10] □□□□□□□□□□ . □□□□□□□□□□□□□□□□□□□ . 2022.

Revision #6
Created 2025-12-12 07:47:26 UTC by Colin Wang
Updated 2025-12-12 13:38:25 UTC by Colin Wang